ß-thalassemia Clinical Trial
Official title:
Safety and Efficacy of Lentiviral Vector Transduction of β-globin Genetically Modified Autologous CD34+ Hematopoietic Stem Cells in Patients With Transfusion-dependent β-thalassemia
This study will be intented to evaluate the safety, tolerability, and engraftment efficacy after myeloablative preconditioning and transplantation of autologous CD34+ hematopoietic stem cells transduced with a lentiviral vector encoding the human βA-T87Q-globin gene in patients with transfusion-dependent (TDT) β-thalassemia.
This is an open-label, single-dose study of BD211 in patients with transfusion-dependent β-thalassemia aged 3 to 18 years. It is estimated that 10 subjects will be enrolled. BD211 is a gene modified gene therapy product designed to produce healthy β-globin in red blood cells in beta-thalassemia patients. The total follow-up duration was 24 months, the safe endpoints and effectiveness endpoints will be used to assess the safety and efficacy profiles in patients with transfusion-dependent β-thalassemia. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00560820 -
Phase I Study to Examine the Effect of Deferasirox on Renal Hemodynamics in β-thalassemia Patients With Transfusional Iron Overload
|
Phase 1 | |
| Recruiting |
NCT05864170 -
the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia
|
Early Phase 1 | |
| Completed |
NCT04054921 -
Safety Study for Beta Thalassemia Subjects on PTG-300
|
Phase 2 | |
| Not yet recruiting |
NCT06440603 -
EKLF Gene Expression in β-thalassemia
|
||
| Recruiting |
NCT06465550 -
A Phase 1 Study of the Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cell in β-thalassemia Major
|
Phase 1 | |
| Completed |
NCT03802201 -
Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia
|
Phase 2 | |
| Recruiting |
NCT05745532 -
Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients
|
Early Phase 1 | |
| Not yet recruiting |
NCT03358498 -
Quality of Life and Treatment Satisfaction in β-Thalassemia Patients Receiving Deferasirox
|
N/A | |
| Recruiting |
NCT05494333 -
Correlation Between Pulmonary Functions and Physical Fitness in Children With β-thalassemia
|